Abstract:BACKGROUND. Drug-eluting bead transarterial chemoembolization (DEB-TACE) has emerged as an alternative to conventional TACE (cTACE) for treatment of hepatocellular carcinoma (HCC), although selection between the approaches remains controversial. OBJECTIVE. The purpose of this study was to compare DEB-TACE and cTACE in the treatment of patients with unresectable HCC in terms of hepatobiliary changes on imaging and clinical complications. METHODS. This retrospective study included 1002 patients (871 men, 131 women; mean age, 59 +/- 12 years) from three centers who had previously untreated unresectable HCC and underwent DEB TACE with epirubicin (780 procedures in 394 patients) or cTACE with ethiodized oil mixed with doxorubicin and oxaliplatin (1187 procedures in 608 patients) between May 2016 and November 2018. Among these patients 83.4% had hepatitis B-related liver disease, 57.6% had Barcelona Clinic Liver Cancer (BCLC) stage A or B HCC, and 42.4% had three or more nodules. Mean tumor size was 6.3 +/- 4.2 cm. Hepatobiliary changes and tumor response were evaluated with CT or MRI 1 month after TACE. Clinical records were reviewed for adverse events. RESULTS. Bile duct dilatation (p <.001) and portal vein narrowing (p =.006) on imaging and liver failure (p = .03) and grade 3 abdominal pain (p < .001) in clinical follow-up occurred at higher frequency in the DEB-TACE group (15.5%, 4.6%, 2.3%, and 6.1%) than in the cTACE (7A%, 1.6%, 0.7%, and 2.1%) group. Higher frequency of bile duct dilation in patients who underwent DEB TACE was observed in subgroup analyses that included patients with BCLC stage A or B HCC (p = .001), with cirrhosis (p < .001), without cirrhosis (p = .04), and without main portal vein tumor thrombus (p = .002). Total bilirubin level 1 month after treatment was 1.5 +/- 2.4 mg/dL (95% CI, 1.2-1.8 mg/dL) for DEB TACE versus 1.3 +/- 2.0 mg/dL (95% CI, 1.1-1.5 mg/dL) for cTACE (p = .02). The cTACE and DEB TACE groups did not differ in other manifestations of postembolization syndrome or systemic toxicity (p > .05). Local tumor disease control rates did not differ between the cTACE and DEB-TACE groups (1 month, 96.7% vs 98.5%, p = .06; 3 months, 81.8% vs 82.4%, p .87), but overall DCR was significantly higher in the cTACE than in the DEB-TACE group (1 month, 87.5% vs 80.0%, p = .001; 3 months, 78.5% vs 72.1%, p = .02). CONCLUSION. Compared with cTACE, DEB TACE was associated with greater frequency of hepatobiliary injury and severe abdominal pain. CLINICAL IMPACT. Greater caution and closer follow-up are warranted for patients who undergo DEB-TACE for unresectable HCC than for those who undergo cTACE.

Treatment Response, Survival, and Safety of Transarterial Chemoembolization With CalliSpheres® Microspheres Versus Conventional Transarterial Chemoembolization in Hepatocellular Carcinoma: A Meta-Analysis

Efficacy And Safety Of Drug-Eluting Beads Transarterial Chemoembolization By Callispheres (R) In 275 Hepatocellular Carcinoma Patients: Results From The Chinese Callispheres (R) Transarterial Chemoembolization In Liver Cancer (Ctilc) Study

Safety And Efficacy Of Drug-Eluting Bead Transarterial Chemoembolization With Callispheres (R) Microsphere For Hepatocellular Carcinoma With Portal Vein Tumor Thrombus: A Preliminary Study

[Clinical Investigation on Transarterial Chemoembolization with Indigenous Drug-Eluting Beads in Treatment of Unresectable Hepatocellular Carcinoma].

The Comprehensive Analysis Of Efficacy And Safety Of Callispheres (R) Drug-Eluting Beads Transarterial Chemoembolization In 367 Liver Cancer Patients: A Multiple-Center, Cohort Study

Comparison of Treatment Response, Survival Profiles, as Well as Safety Profiles Between CalliSpheres® Microsphere Transarterial Chemoembolization and Conventional Transarterial Chemoembolization in Huge Hepatocellular Carcinoma

Efficacy and safety of CalliSpheres microsphere versus conventional transcatheter arterial chemoembolization in treatment of hepatocellular carcinoma: A Meta-analysis

Comparison of Chemoembolization with CalliSpheres® Microspheres and Conventional Chemoembolization in the Treatment of Hepatocellular Carcinoma: a Multicenter Retrospective Study.

Drug-eluting Bead Transarterial Chemoembolization (TACE) Exhibits Superior Efficacy and Equal Tolerance to Conventional TACE in Hepatocellular Carcinoma Patients with Conventional TACE History

Imaging Changes and Clinical Complications After Drug-Eluting Bead Versus Conventional Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma: Multicenter Study

Conventional Transarterial Chemoembolization Vs Microsphere Embolization in Hepatocellular Carcinoma: A Meta-Analysis

Comparison of Liver Function and Safety in Hepatocellular Cancer Patients Treated with DEB-TACE and Ctace: a Multi-Center, Retrospective Cohort Study

Efficacy and safety of CalliSpheres (R) drug-eluting beads transarterial chemoembolization in patients with secondary liver cancer: a preliminary result from CTILC study

Drug-eluting Beads Transarterial Chemoembolization by CalliSpheres is Effective and Well Tolerated in Treating Intrahepatic Cholangiocarcinoma Patients

CalliSpheres drug-eluting beads versus lipiodol transarterial chemoembolization in the treatment of hepatocellular carcinoma: a short-term efficacy and safety study

Efficacy and safety of drug-eluting beads for transarterial chemoembolization in patients with advanced hepatocellular carcinoma.

Assessment of efficacy and safety by CalliSpheres versus HepaSpheres for drug-eluting bead transarterial chemoembolization in unresectable large hepatocellular carcinoma patients

Efficacy and Safety of Ctace Versus DEB‐TACE in Patients with Hepatocellular Carcinoma: a Meta‐analysis

A Comparison Between Drug-Eluting Bead-Transarterial Chemoembolization and Conventional Transarterial Chemoembolization in Patients with Hepatocellular Carcinoma: A Meta-Analysis of Six Randomized Controlled Trials.

Safety and efficacy of drug-eluting bead transarterial chemoembolization with CalliSpheres® microsphere for hepatocellular carcinoma with portal vein tumor thrombus: a preliminary study

Evaluation of Drug-Eluting Beads Versus Conventional Transcatheter Arterial Chemoembolization in Patients with Unresectable Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis.